Sec Form 5 Filing - SHEEDY CHARLES E @ Nuo Therapeutics, Inc. - 2020-12-31

FORM 5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person SHEEDY CHARLES E 2. Issuer Name and Ticker or Trading Symbol Nuo Therapeutics, Inc. [ AURX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 2907 TWO HOUSTON CENTER 3. Date of Earliest Transaction (MM/DD/YY) 12/31/2020 (Street) HOUSTION, TX77010 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 10/05/2020 J( 1 ) 302,205 A $ 0.4 8,588,517 D Common Stock 10/05/2020 P( 2 ) 175,000 A $ 0.4 8,763,517 D Common Stock 3,365 I( 3 ) Shares held in separate trusts for the benefit of children of the Reporting Person (673 shares in ea

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Warrants to purchase Common Stock $ 0.4 10/05/2020 J 1,431,615( 4 ) 10/05/2020 10/05/2025 Common Stock 1,431,615 $ 0( 5 ) 1,431,615 D Warrants to purchase Common Stock $ 0.4 10/05/2020 J 165,000( 6 ) ( 7 ) ( 7 ) Common Stock 165,000 $ 0( 5 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other SHEEDY CHARLES E 2907 TWO HOUSTON CENTER HOUSTION, TX77010 X Signatures /s/ Charles E. Sheedy 04/26/2022 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Conversion shares acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 ( 2 )Purchase shares acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 ( 3 )The Reporting Person disclaims beneficial ownership over such shares except to the extent of his pecuniary interest therein. ( 4 )Acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 ( 5 )The reported transactions involved a recapitalization resulting in the deemed cancellation of the "old" warrants and the deemed grant of "replacement" warrants. ( 6 )Cancelled in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020 ( 7 )Originally exercisable on 11/15/19 and 12/06/19, with expirations of 11/15/24 and 12/06/24, respectively, for 15,000 shares and 150,000 shares

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.